Introduction: Homozygous familial hypercholesterolaemia (HoFH) is a rare form of inherited dyslipidemia resistant to conventional cholesterol-lowering medications so that lipoprotein apheresis (LA) is usually required. Lomitapide has been approved for the treatment of HoFH. The aim of this study was to evaluate the benefits of lomitapide in HoFH patients followed with the usual clinical care. Methods: Clinical and biochemical data were retrospectively collected in 15 HoFH patients (10 with mutations in the LDLR gene and 5 in the LDLRAP1 gene) treated for at least 6 months with lomitapide in addition to lipid-lowering therapies (LLT) in different Lipid Clinics across Italy. Results: The mean follow-up period was 32.3 ± 29.7 months. During background therapies, HoFH patients showed a mean LDL-C level of 426.0 ± 204.0 mg/dl. The addition of lomitapide at the average dosage of 19 mg/day lowered LDL-C levels by 68.2 ± 24.8%. At their last visit, 60% of patients showed LDL-C\100 mg/ dl and 46.6%\70 mg/dl. During follow-up, 8 of 10 patients receiving LA (80%) stopped thistreatment due to marked LDL-C reduction. A wide range (13–95%) of individual LDL-C reduction was observed, but this was not related to genotype. During follow-up, 53.3% of patients reported at least one episode of diarrhea, but none was referred as severe; none had liver transaminase[59 ULN or had to stop treatment due to side effects. A subset of patients was evaluated by liver ultrasound and fibroscan (n = 5) or nuclear magnetic resonance with spectroscopy (MRS) (n = 1) not showing clinical evidence of liver damage. Conclusion: In this real-world experience, lomitapide was confirmed to be a very powerful cholesterol-lowering agent in HoFH showing a good safety profile.

Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy / D'Erasmo, Laura; Cefalù, Angelo Baldassare; Noto, Davide; Giammanco, Antonina; Averna, Maurizio; Pintus, Paolo; Medde, Paolo; Vigna, Giovanni Battista; Sirtori, Cesare; Calabresi, Laura; Pavanello, Chiara; Bucci, Marco; Sabbà, Carlo; Suppressa, Patrizia; Natale, Francesco; Calabrò, Paolo; Sampietro, Tiziana; Bigazzi, Federico; Sbrana, Francesco; Bonomo, Katia; Sileo, Fulvio; Arca, Marcello. - In: ADVANCES IN THERAPY. - ISSN 0741-238X. - STAMPA. - (2017), pp. 1-11. [10.1007/s12325-017-0531-x]

Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy

D'ERASMO, LAURA;ARCA, Marcello
2017

Abstract

Introduction: Homozygous familial hypercholesterolaemia (HoFH) is a rare form of inherited dyslipidemia resistant to conventional cholesterol-lowering medications so that lipoprotein apheresis (LA) is usually required. Lomitapide has been approved for the treatment of HoFH. The aim of this study was to evaluate the benefits of lomitapide in HoFH patients followed with the usual clinical care. Methods: Clinical and biochemical data were retrospectively collected in 15 HoFH patients (10 with mutations in the LDLR gene and 5 in the LDLRAP1 gene) treated for at least 6 months with lomitapide in addition to lipid-lowering therapies (LLT) in different Lipid Clinics across Italy. Results: The mean follow-up period was 32.3 ± 29.7 months. During background therapies, HoFH patients showed a mean LDL-C level of 426.0 ± 204.0 mg/dl. The addition of lomitapide at the average dosage of 19 mg/day lowered LDL-C levels by 68.2 ± 24.8%. At their last visit, 60% of patients showed LDL-C\100 mg/ dl and 46.6%\70 mg/dl. During follow-up, 8 of 10 patients receiving LA (80%) stopped thistreatment due to marked LDL-C reduction. A wide range (13–95%) of individual LDL-C reduction was observed, but this was not related to genotype. During follow-up, 53.3% of patients reported at least one episode of diarrhea, but none was referred as severe; none had liver transaminase[59 ULN or had to stop treatment due to side effects. A subset of patients was evaluated by liver ultrasound and fibroscan (n = 5) or nuclear magnetic resonance with spectroscopy (MRS) (n = 1) not showing clinical evidence of liver damage. Conclusion: In this real-world experience, lomitapide was confirmed to be a very powerful cholesterol-lowering agent in HoFH showing a good safety profile.
2017
cholesterol-lowering effect; clinical practice; genetics; lomitapide; severe hypercholesterolemia; medicine (all); pharmacology (medical)
01 Pubblicazione su rivista::01a Articolo in rivista
Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy / D'Erasmo, Laura; Cefalù, Angelo Baldassare; Noto, Davide; Giammanco, Antonina; Averna, Maurizio; Pintus, Paolo; Medde, Paolo; Vigna, Giovanni Battista; Sirtori, Cesare; Calabresi, Laura; Pavanello, Chiara; Bucci, Marco; Sabbà, Carlo; Suppressa, Patrizia; Natale, Francesco; Calabrò, Paolo; Sampietro, Tiziana; Bigazzi, Federico; Sbrana, Francesco; Bonomo, Katia; Sileo, Fulvio; Arca, Marcello. - In: ADVANCES IN THERAPY. - ISSN 0741-238X. - STAMPA. - (2017), pp. 1-11. [10.1007/s12325-017-0531-x]
File allegati a questo prodotto
File Dimensione Formato  
D'Erasmo_Efficacy-Lomitapide_2017.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 585 kB
Formato Adobe PDF
585 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/952625
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 52
  • ???jsp.display-item.citation.isi??? 49
social impact